Published in Blood Weekly, August 21st, 2008
"Here, we investigated the utility of Pax-2 immunohistochemistry (IHC) for RCC in cytologic material, in comparison with a variety of other neoplasms. Pax-2 IHC was performed on cell block sections of 33 RCCs (14 primary, 19 metastatic) and 35 non-RCC malignancies, including 26 carcinomas, five mesenchymal tumors, one neuroblastoma, two melanomas, and one lymphoma, from fine-needle aspirations and body...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2008-08-21)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.